Ignite Creation Date:
2024-05-05 @ 11:49 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00144105
Status:
TERMINATED
Last Update Posted:
2013-11-01
First Post:
2005-09-02
Brief Title:
A Randomised Trial to Evaluate the Antiviral Efficacy and Safety of Treatment With 500 mg Tipranavir TPV Plus 100 mg or 200 mg Ritonavir RTV po BID in Comparison to 400 mg Lopinavir LPV Plus 100 mg RTV po BID in Combination With Standard Background Regimen in ARV Therapy naïve Patients
Sponsor:
Organization:
Boehringer Ingelheim
Study Design
Study Type:
INTERVENTIONAL
Expanded Access Type Individual:
None
Expanded Access Type Intermediate:
None
Expanded Access Type Treatment:
None
Patient Registry:
None
Target Duration:
None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention:
None
Bio Spec Description:
None
Enrollment Count:
562
Enrollment Type:
ACTUAL
Design Primary Purpose:
Design Masking:
Phases:
| Name |
|---|
| PHASE2 |
Observational Models:
Time Perspective List:
Who Masked List: